Revolutionizing Multiple Myeloma: Immunotherapy Is Transforming Treatment, Extending Lives, Dr Mohamad Mohty Says
Mohamad Mohty, MD, PhD, of Saint-Antoine Hospital and Sorbonne University, highlights how immunotherapies are offering various effective treatment options for patients with multiple myeloma and improving quality of life for relapsed/refractory patients.
Mohamad Mohty, MD, PhD, professor of hematology and head of the hematology and cellular therapy department at Sorbonne University and Saint-Antoine Hospital, discusses how immunotherapies have significantly transformed
Mohty explored this topic further during the session he chaired, "Immunotherapy in Multiple Myeloma: A New Frontier on the Road to Cure," at the
Transcript
How has immunotherapy transformed the landscape of multiple myeloma treatment in recent years?
Immunotherapy is really proving to be a transformative therapy for multiple myeloma. For many years, we've been, I would say, waiting for the advent of immunotherapy, whether cellular immune therapy with CAR [chimeric antigen receptor] T cells. The CAR T cells were approved in multiple myeloma after approval of CAR T cells in lymphoma but also
Immunotherapy with bispecific antibodies, now we're fortunate having 3 bispecific antibodies approved: 2 against BCMA [B-cell maturation antigen],
You can see the development is moving rapidly with several candidates, but we have also proven efficacy and well-established safety profiles. All of these immunotherapies are really modifying the natural history of multiple myeloma patients who are in relapsed/refractory disease, especially those patients who are triple refractory or even penta-refractory.
Until recently, we didn't have any effective treatment options for these patients. These are patients who are supposed to be in supportive palliative care, and now we have dozens of patients who are enjoying long-term survival with good quality of life. So, overall, immunotherapies have been transformative, I would say, in the myeloma landscape; this is really, really very good news.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Related Articles
- Sotatercept Shows Right Heart Gains in PAH: Anjali Vaidya, MD
September 17th 2025
- Cost-Effectiveness of Varying Weight Loss Interventions: Elena Losina, PhD
September 17th 2025
- Linvoseltamab: A New Horizon for Relapsed Myeloma
September 17th 2025